GSK1370319A

• CAT Number: I028316
• CAS Number: 1001389-31-6
• Molecular Formula: C13H14Cl2N2O2
• Molecular Weight: 301.17
• Purity: 98%
• Synonyms: GSK1370319A; GSK-1370319A; GSK 1370319A; GSK1370319; GSK-1370319; GSK 1370319
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: (2S)-N-[(2,4-Dichlorophenyl)methyl]-1-methyl-5-oxo-2-pyrrolidinecarboxamide
• InChI: InChI=1S/C13H14Cl2N2O2/c1-17-11(4-5-12(17)18)13(19)16-7-8-2-3-9(14)6-10(8)15/h2-3,6,11H,4-5,7H2,1H3,(H,16,19)/t11-/m0/s1
• InChIKey: YMNOJCVLDDTECB-NSHDSACASA-N
• SMILES: ClC1=CC=C(C(Cl)=C1)CNC([C@H]2N(C(CC2)=O)C)=O

GSK1370319A (Cat No.: I028316) is a small-molecule compound developed by GlaxoSmithKline, primarily used in research to investigate its biological activity and therapeutic potential. While its specific mechanism of action is not widely published, compounds like GSK1370319A are typically explored for their role in modulating key signaling pathways or molecular targets in areas such as oncology, immunology, or neurology. As part of early-stage drug discovery, it serves as a tool compound for target validation, pharmacological profiling, and structure-activity relationship (SAR) studies in medicinal chemistry.

Reference

1: Homerin G, Jawhara S, Dezitter X, Baudelet D, Dufrénoy P, Rigo B, Millet R,
Furman C, Ragé G, Lipka E, Farce A, Renault N, Sendid B, Charlet R, Leroy J,
Phanithavong M, Richeval C, Wiart JF, Allorge D, Adriouch S, Vouret-Craviari V,
Ghinet A. Pyroglutamide-Based P2X7 Receptor Antagonists Targeting Inflammatory
Bowel Disease. J Med Chem. 2019 Sep 17. doi: 10.1021/acs.jmedchem.9b00584. [Epub
ahead of print] PubMed PMID: 31525963.
2: McHugh SM, Roman S, Davis B, Koch A, Pickett AM, Richardson JC, Miller SR,
Wetten S, Cox CJ, Karpe F, Todd JA, Bullmore ET. Effects of genetic variation in
the P2RX7 gene on pharmacodynamics of a P2X(7) receptor antagonist: a prospective
genotyping approach. Br J Clin Pharmacol. 2012 Aug;74(2):376-80. doi:
10.1111/j.1365-2125.2012.04200.x. PubMed PMID: 22295949; PubMed Central PMCID:
PMC3630758.
3: Murphy N, Cowley TR, Richardson JC, Virley D, Upton N, Walter D, Lynch MA. The
neuroprotective effect of a specific P2X₇ receptor antagonist derives from its
ability to inhibit assembly of the NLRP3 inflammasome in glial cells. Brain
Pathol. 2012 May;22(3):295-306. doi: 10.1111/j.1750-3639.2011.00531.x. Epub 2011
Oct 27. PubMed PMID: 21933296.